JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc
Search

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

32.16 -2.25

Strong Buy

Prijsupdate 1 mei 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.08

Max

32.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-81M

Verkoop

75K

75K

EPS

-1.22

Winstmarge

-108,422.667

Werknemers

198

EBITDA

-7.8M

-81M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+75.18% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1B

2.6B

Vorige openingsprijs

34.41

Vorige sluitingsprijs

32.16

Nieuwssentiment

By Acuity

50%

50%

176 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lezen

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lezen

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lezen

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lezen

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lezen

4 mei 2026, 22:37 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lezen

4 mei 2026, 22:26 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lezen

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lezen

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lezen

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lezen

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

75.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.6 USD  75.18%

Hoogste 90 USD

Laagste 34 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

176 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

224.16

↓-1.45%

UNH

UnitedHealth Group Inc

370.76

↑ +0.47%

TMO

Thermo Fisher Scientific Inc

462.35

↓-1.48%

ISRG

Intuitive Surgical Inc

452.39

↓-1.14%

ABT

Abbott Laboratories

87.56

↓-2.18%
help-icon Live chat